Home > Drug Search >
  • Targets: Cluster of Differentiation 22 (CD22)
  •   > 
Drug Filter
Category:
chemistry (13) biology (11)
Status:
Approved (4) Phase Ⅲ (3) Phase Ⅱ (10) Phase Ⅰ (7)
Clinical Stage:
Pending (3) Active (12) Discontinued (5)
Bio-Type:
CAR T cell therapy (2) Whole antibody (3) ADC (6)
Company:
Ferring Pharmaceuticals (2) Genentech (1) Immunomedics (2) Kyowa Hakko Kirin (1) MedImmune (1) National Cancer Institute (3) Novartis (1) Otsuka (1) Pfizer (1) Roche (1) Sanofi (1) Teva (1) UCB (2) University of Texas Southwestern Medical Center (2) Juno Therapeutics (1) Opus Bio (1) University of Minnesota (1) Lonn Ryonn Pharma (1) SinoMab Bioscience Ltd (1) Galileo Research (1) Nantes University Hospital (1) Oxis International (1) Arno Therapeutics (1) University of Pennsylvania (1) Azevan (2) Vantia (1) Allergan (1) Astellas (1)
Indication:
Acne (1) Acute lymphoblastic leukaemia (ALL) (6) Alcohol dependence (1) Chronic lymphocytic leukemia (CLL) (1) Dysmenorrhea (3) Heart failure (1) Hypertension (1) Hyponatremia (1) Leukemia (2) Lymphoma (2) Melanoma (1) Non-Hodgkin B-cell lymphomas (1) Non-Hodgkin’s lymphoma (NHL) (3) Ovarian cancer (1) Pancreatic cancer (1) Rheumatoid arthritis (RA) (1) Sjoegren's syndrome (1) Small cell lung cancer (SCLC) (2) Solid tumours (2) Systemic lupus erythematosus (2) Hypervolemic hyponatremia (1) Autistic disorder (1) B-cell lymphoma (4) Hairy cell leukemia (1) Refractory ascites (1) Septic shock (1) Intermittent explosive disorder (1) Diffuse large B cell lymphoma (2)
Country:
US (1) EU (1) FR (1)
Aprv. Year:
1995 (1) 2005 (1) 2017 (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 2 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top